Abstract
Importance of the field: Vinorelbine is a 'third-generation' vinca alkaloid approved for the treatment of NSCLC. The introduction of 'third-generation' drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with substantially similar results among the different drugs. Treatment toxicities are considerable in this setting. Areas covered in this review: This narrative review reports a synthesis of evidence available from published clinical trials, systematic reviews and meta-analyses on the activity and safety of vinorelbine, used as single agent or in combination chemotherapy in patients with NSCLC, from 1990 to 2009. What the reader will gain: When vinorelbine was administered in a weekly schedule without interruptions, the most common toxicity was neutropenia that often precluded administration of the drug, therefore, reducing the dose intensity. A schedule providing administration of vinorelbine on days 1 and 8 every 3 weeks seemed to improve the tolerability of the drug. Tolerability of the drug did not result lower in the elderly subset. None of the other 'third-generation' drugs were clearly better tolerated than vinorelbine. Moreover, in the adjuvant setting, vinorelbine is the only third-generation drug that demonstrated, in combination with cisplatin, a consistent improvement in survival on a long-term basis. Take home message: Vinorelbine is an active and generally manageable therapeutic option for the treatment of both early and advanced NSCLC.
| Original language | English |
|---|---|
| Pages (from-to) | 493-510 |
| Number of pages | 18 |
| Journal | Expert Opinion on Drug Safety |
| Volume | 9 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - May 2010 |
Fingerprint
Keywords
- NSCLC
- Platinum combinations
- Safety
- Third-generation drugs
- Vinorelbine
ASJC Scopus subject areas
- Pharmacology (medical)
Cite this
Vinorelbine for non-small cell lung cancer. / Piccirillo, Maria Carmela; Daniele, Gennaro; Di Maio, Massimo; Bryce, Jane; De Feo, Gianfranco; Del Giudice, Antonia; Perrone, Francesco; Morabito, Alessandro.
In: Expert Opinion on Drug Safety, Vol. 9, No. 3, 05.2010, p. 493-510.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Vinorelbine for non-small cell lung cancer
AU - Piccirillo, Maria Carmela
AU - Daniele, Gennaro
AU - Di Maio, Massimo
AU - Bryce, Jane
AU - De Feo, Gianfranco
AU - Del Giudice, Antonia
AU - Perrone, Francesco
AU - Morabito, Alessandro
PY - 2010/5
Y1 - 2010/5
N2 - Importance of the field: Vinorelbine is a 'third-generation' vinca alkaloid approved for the treatment of NSCLC. The introduction of 'third-generation' drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with substantially similar results among the different drugs. Treatment toxicities are considerable in this setting. Areas covered in this review: This narrative review reports a synthesis of evidence available from published clinical trials, systematic reviews and meta-analyses on the activity and safety of vinorelbine, used as single agent or in combination chemotherapy in patients with NSCLC, from 1990 to 2009. What the reader will gain: When vinorelbine was administered in a weekly schedule without interruptions, the most common toxicity was neutropenia that often precluded administration of the drug, therefore, reducing the dose intensity. A schedule providing administration of vinorelbine on days 1 and 8 every 3 weeks seemed to improve the tolerability of the drug. Tolerability of the drug did not result lower in the elderly subset. None of the other 'third-generation' drugs were clearly better tolerated than vinorelbine. Moreover, in the adjuvant setting, vinorelbine is the only third-generation drug that demonstrated, in combination with cisplatin, a consistent improvement in survival on a long-term basis. Take home message: Vinorelbine is an active and generally manageable therapeutic option for the treatment of both early and advanced NSCLC.
AB - Importance of the field: Vinorelbine is a 'third-generation' vinca alkaloid approved for the treatment of NSCLC. The introduction of 'third-generation' drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with substantially similar results among the different drugs. Treatment toxicities are considerable in this setting. Areas covered in this review: This narrative review reports a synthesis of evidence available from published clinical trials, systematic reviews and meta-analyses on the activity and safety of vinorelbine, used as single agent or in combination chemotherapy in patients with NSCLC, from 1990 to 2009. What the reader will gain: When vinorelbine was administered in a weekly schedule without interruptions, the most common toxicity was neutropenia that often precluded administration of the drug, therefore, reducing the dose intensity. A schedule providing administration of vinorelbine on days 1 and 8 every 3 weeks seemed to improve the tolerability of the drug. Tolerability of the drug did not result lower in the elderly subset. None of the other 'third-generation' drugs were clearly better tolerated than vinorelbine. Moreover, in the adjuvant setting, vinorelbine is the only third-generation drug that demonstrated, in combination with cisplatin, a consistent improvement in survival on a long-term basis. Take home message: Vinorelbine is an active and generally manageable therapeutic option for the treatment of both early and advanced NSCLC.
KW - NSCLC
KW - Platinum combinations
KW - Safety
KW - Third-generation drugs
KW - Vinorelbine
UR - http://www.scopus.com/inward/record.url?scp=77951637766&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951637766&partnerID=8YFLogxK
U2 - 10.1517/14740331003774078
DO - 10.1517/14740331003774078
M3 - Article
C2 - 20350282
AN - SCOPUS:77951637766
VL - 9
SP - 493
EP - 510
JO - Expert Opinion on Drug Safety
JF - Expert Opinion on Drug Safety
SN - 1474-0338
IS - 3
ER -